AZ COVID-19 Vaccine Scores 79% In Pivotal US Trial – Any Hope For A Fresh Start?
Brain Clot Safety Issue Addressed
The US FDA will now have the full efficacy data that it wanted from AstraZeneca, but the company still has to deal with concerns over safety and global supply issues.
You may also be interested in...
‘Harsh note’ from Data Safety and Monitoring Board follows AstraZeneca press release that contained incomplete information about the Phase III US trial for its COVID vaccine. It remains to be seen how the company will fix this ‘unforced error’ and weather the latest threat to public trust.
A new “unforced error” from AstraZeneca in reporting clinical data is keeping its COVID-19 vaccine in the headlines for the wrong reasons.
The procurement and authorization of vaccines are under scrutiny in the European Parliament this week. In the meantime, another Sputnik V spat is taking wing between Russia and the EU, while France has resumed the use of AstraZeneca’s vaccine, but only in the over-55s.